hepatitis%20a%20-and-%20e
HEPATITIS A & E

Hepatitis A route of transmission is through oral-fecal route while in hepatitis E, aside from the oral-fecal route, it is also transmitted through blood transfusion in endemic areas.

Hepatitis A incubation period is 15-50 days and hepatitis E incubation period is 15-60 days.

Hepatitis A & E viruses cause epidemics.

 

Hepatitis%20a%20-and-%20e Diagnosis

History

Important Points in the Clinical History of Patients with Suspected Viral Hepatitis

  • Contacts with jaundiced patients
  • IV drug use
  • History of blood transfusion
  • Surgery or hospitalizations
  • Family history of chronic liver disease
  • Occupation
  • Food and water sources

Laboratory Tests

Serological Tests

Hepatitis A

  • Anti-hepatitis A virus (HAV) IgM has high sensitivity and specificity and is a marker of acute infection
    • This test remains positive for ≥6 months
  • Anti-HAV should be tested in patients <50 years

Hepatitis E

  • IgM anti-HEV, IgG anti-HEV in combination with hepatitis E virus (HEV) RNA indicate acute hepatitis E infection
  • Detection of HEV antigen by enzyme immunoassays may also be used to diagnose both acute and chronic infections
  • HEV genotype should be determined, if possible, in all HEV-infected persons prior to treatment to determine type and duration of therapy and chances of response; predominant genotypes worldwide are:
    • Genotype 1: Africa and Asia
    • Genotype 2: Mexico, West Africa
    • Genotype 3: Developed countries
    • Genotype 4: China, Taiwan, Japan

Tests to Rule Out Other Viral Hepatitis

  • Hepatitis B: Hepatitis B surface antigen (HBsAg), hepatitis B core antibody (anti-HBc), hepatitis B e antigen (HBeAg)
  • Hepatitis C: Anti-hepatitis C virus (anti-HCV) antibody, HCV RNA test, HCV core antigen
  • Hepatitis D: Anti-hepatitis D virus (anti-HDV) antibody, HDV RNA test
  • Please see Hepatitis B and Hepatitis C disease management charts for further information

Nucleic Acid Amplification Test (NAAT)

  • Eg conventional reverse transcription polymerase chain reaction (RT-PCR), real-time RT-PCR, transcription-mediated amplification methods, genotyping for HAV RNA or HEV RNA may be considered
  • HEV RNA is detected from serum and stool of infected patients by NAAT-based assays

Immunohistochemistry

  • HEV ORF2 protein immunohistochemistry can be used to establish a histopathologic diagnosis of hepatitis E

Other Recommended Lab Tests in Patients Suspected of Viral Hepatitis

  • Liver function tests (LFTs)
    • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT)
    • Serum bilirubin, alkaline phosphatase (ALP)
  • Prothrombin time (PT), international normalized ratio (INR), complete blood count (CBC) with platelets, renal function tests
  • Noninvasive tests such as the aminotransferase/platelet ratio index (APRI) or FIB4 may be used to assess the degree of hepatic fibrosis when resources are limited prior to initiating HCV therapy
    • Transient elastography may be an option for patients with contraindications to liver biopsy

Evaluation

Features of Hepatic Decompensation

  • Mental dullness, hepatic encephalopathy, bilateral asterixis, ascites, clinical deterioration
  • Serum bilirubin >2.5x upper limit of normal, PT is 3 seconds longer than control or INR >1.5

Biochemical or Clinical Improvement

  • Repeat liver function test and serum/stool HEV RNA detection will show normalization if patient responded to treatment or infection subsided spontaneously
  • Repeat anti-HAV IgM after 1 week may be used to determine if acute or recent infection has resolved
  • Refer to a specialist if tests are still positive for infection and with disease persistence or progression
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 2 days ago
Reductions in liver fat and adipose tissue volumes were sustained in patients with type 2 diabetes (T2D) with the addition of the SGLT-2* inhibitor dapagliflozin (DAPA) and the DPP-4** inhibitor saxagliptin (SAXA) to metformin (MET), compared with a regimen comprising glimepiride (GLIM)+MET, according to the extension period results of a phase IIIb trial.